News Overview

It is used with Durvalumab to treat advanced or recurrent endometrial cancer in patients whose disease has not progressed after first-line treatment.

For the July-September 2024 quarter, UltraTech Cement reported a net profit of ₹825 crore, a drop of 36% from ₹1,280 crore it had registered for the same period last year.

This is in the wake of an ongoing review by the Directorate General of Goods and Services Tax Intelligence related to Dabur's tax compliance.

The total contract value is of ₹625.08 crore, including GST, with an expected time of completion of 30 months.

The three-year contract will involve TCS maintaining both the hardware and software of the system while implementing updates to enhance operations.

  Shilpa Medicare is the first Indian company to gain approval for Phase III trials of Recombinant Human Albumin.

Its module order is likely to be supplied starting FY 2025-26 and comes out from its own exchange filing.

Patanjali Foods reported a net profit of ₹309 crore for Q2 FY25, showing a 21.4% year-on-year growth compared to ₹254.5 crore in Q2 FY24.

The move resonates with Exide's commitment towards sustainable energy solutions and its role in driving India's transition to electric mobility and renewable energy.

The IPO was oversubscribed 12.52 times on the second day of public subscription. Today is the third and last day of bidding on the issue.